Lin Y L, Borenstein L A, Selvakumar R, Ahmed R, Wettstein F O
Department of Microbiology and Immunology, School of Medicine, University of California, Los Angeles 90024.
Virology. 1992 Apr;187(2):612-9. doi: 10.1016/0042-6822(92)90463-y.
Immunization of rabbits with either L1, the major structural protein, or L2, a minor structural protein of cottontail rabbit papillomavirus (CRPV), protected against challenge with the virus. Neutralizing antibodies were elicited by both the L1 and L2 trpE fusion proteins. Neutralization with anti-L1 serum, however, was more efficient than with anti-L2 serum. In contrast, when tested on Western blots the immune response to L2 was stronger than to L1. Rabbits were also protected against CRPV infection by immunization with L1 expressing recombinant vaccinia virus. Sera from two of three rabbits immunized with recombinant vaccinia virus were negative on Western blots but all three were positive in ELISA's with nondenatured fusion protein or in immunoprecipitations. The results suggest that both the viral structural proteins, L1 and L2, merit consideration in the development of a vaccine against papillomavirus.
用棉尾兔乳头瘤病毒（CRPV）的主要结构蛋白L1或次要结构蛋白L2免疫兔子，可使其免受该病毒的攻击。L1和L2 trpE融合蛋白均可诱导产生中和抗体。然而，用抗L1血清进行中和比用抗L2血清更有效。相反，在蛋白质印迹法检测时，对L2的免疫反应比对L1更强。用表达L1的重组痘苗病毒免疫兔子也可使其免受CRPV感染。用重组痘苗病毒免疫的三只兔子中，有两只兔子的血清在蛋白质印迹法检测中呈阴性，但在使用未变性融合蛋白的酶联免疫吸附测定（ELISA）或免疫沉淀试验中，三只兔子的血清均呈阳性。结果表明，病毒结构蛋白L1和L2在乳头瘤病毒疫苗的研发中均值得考虑。
